DNA interaction with platinum-based cytostatics revealed by DNA sequencing

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Platinum-based drugs (cisplatin, oxaliplatin, carboplatin) are cytostatic agents.
• Their primary mechanism involves forming DNA cross-links, impeding transcription by blocking DNA polymerase access.
• Understanding the differential effects of these drugs is crucial for optimizing cancer therapy.

Purpose of the Study:

• To model the effect of platinum-based cytostatics on DNA using polymerase chain reaction (PCR).
• To assess the impact of DNA-drug cross-links on DNA labeling efficiency.
• To compare the relative potencies of cisplatin, oxaliplatin, and carboplatin in vitro.

Main Methods:

• Utilized PCR as a simplified model of DNA amplification within a cell nucleus.
• Employed fluorescently labeled dideoxynucleotides, typically used in DNA sequencing, to monitor labeling efficiency.
• Quantified platinum incorporation using inductively coupled plasma mass spectrometry (ICP-MS).

Main Results:

• Significantly different drug concentrations were required to achieve a 50% quenching effect on DNA fluorescent labeling: cisplatin (0.21 μg/mL), oxaliplatin (5.23 μg/mL), and carboplatin (71.11 μg/mL).
• Despite orders of magnitude differences in applied drug amounts, the incorporated platinum levels per DNA mass were comparable across all tested drugs.
• Demonstrated a dose-dependent relationship between platinum-drug concentration and reduced labeling efficiency.

Conclusions:

• The study highlights the varying potencies of common platinum-based chemotherapy drugs in vitro.
• PCR serves as a viable model to assess the functional impact of DNA-crosslinking agents.
• Comparable platinum incorporation suggests differences in drug-DNA interaction and cellular processing contribute to their distinct efficacies.